Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week.
De Caterina R, Agewall S, Andreotti F, Angiolillo DJ, Bhatt DL, Byrne RA, Collet JP, Eikelboom J, Fanaroff AC, Gibson CM, Goette A, Hindricks G, Lip GYH, Potpara T, Thiele H, Lopes RD, Galli M. De Caterina R, et al. Among authors: gibson cm. Eur Heart J. 2022 Oct 7;43(37):3512-3527. doi: 10.1093/eurheartj/ehac294. Eur Heart J. 2022. PMID: 35925556 No abstract available.
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.
Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, Kleiman NS, Brindis RG, Peacock WF, Brener SJ, Menon V, Smith SC Jr, Pollack CV Jr, Gibler WB, Ohman EM, Roe MT; CRUSADE Investigators. Bhatt DL, et al. Among authors: gibson cm. Eur Heart J. 2009 May;30(10):1195-202. doi: 10.1093/eurheartj/ehp099. Epub 2009 Apr 1. Eur Heart J. 2009. PMID: 19339264
Platelet inhibition with cangrelor in patients undergoing PCI.
Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL. Harrington RA, et al. Among authors: gibson cm. N Engl J Med. 2009 Dec 10;361(24):2318-29. doi: 10.1056/NEJMoa0908628. N Engl J Med. 2009. PMID: 19915221 Free article. Clinical Trial.
Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group.
Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA; Academic Bleeding Consensus Multidisciplinary Working Group. Rao SV, et al. Among authors: gibson cm. Am Heart J. 2009 Dec;158(6):881-886.e1. doi: 10.1016/j.ahj.2009.10.008. Am Heart J. 2009. PMID: 19958852
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).
Leonardi S, Rao SV, Harrington RA, Bhatt DL, Gibson CM, Roe MT, Kochman J, Huber K, Zeymer U, Madan M, Gretler DD, McClure MW, Paynter GE, Thompson V, Welsh RC. Leonardi S, et al. Among authors: gibson cm. Am Heart J. 2010 Jul;160(1):65-72. doi: 10.1016/j.ahj.2010.04.008. Am Heart J. 2010. PMID: 20598974 Clinical Trial.
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Mehran R, et al. Among authors: gibson cm. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. Circulation. 2011. PMID: 21670242 No abstract available.
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial.
Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, Kochman J, McClure MW, Gretler DD, Bhatt DL, Gibson CM, Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi S, Madan M, French WJ, Harrington RA; INNOVATE-PCI Investigators. Welsh RC, et al. Among authors: gibson cm. Circ Cardiovasc Interv. 2012 Jun;5(3):336-46. doi: 10.1161/CIRCINTERVENTIONS.111.964197. Epub 2012 May 29. Circ Cardiovasc Interv. 2012. PMID: 22647518 Clinical Trial.
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
Leonardi S, Stebbins A, Lopes RD, Lokhnygina Y, Todd M, Bhatt DL, Stone GW, Lincoff AM, Dauerman HL, Gibson CM, White HD, Parikh KH, Gruberg L, Herrmann HC, McLaurin BT, Goodman SG, Mahaffey KW. Leonardi S, et al. Among authors: gibson cm. Coron Artery Dis. 2013 Jun;24(4):321-7. doi: 10.1097/MCA.0b013e32835f2fbd. Coron Artery Dis. 2013. PMID: 23442944 Clinical Trial.
803 results